@article{HebestreitZeidlerSchippersetal.2022,
  author    = {Hebestreit, Helge and Zeidler, Cornelia and Schippers, Christopher and de Zwaan, Martina and Deckert, J{\"u}rgen and Heuschmann, Peter and Krauth, Christian and Bullinger, Monika and Berger, Alexandra and Berneburg, Mark and Brandstetter, Lilly and Deibele, Anna and Dieris-Hirche, Jan and Graessner, Holm and G{\"u}ndel, Harald and Herpertz, Stephan and Heuft, Gereon and Lapstich, Anne-Marie and L{\"u}cke, Thomas and Maisch, Tim and Mundlos, Christine and Petermann-Meyer, Andrea and M{\"u}ller, Susanne and Ott, Stephan and Pfister, Lisa and Quitmann, Julia and Romanos, Marcel and Rutsch, Frank and Schaubert, Kristina and Schubert, Katharina and Schulz, J{\"o}rg B. and Schweiger, Susann and T{\"u}scher, Oliver and Ungeth{\"u}m, Kathrin and Wagner, Thomas O. F. and Haas, Kirsten},
  title     = {Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {17},
  journal   = {Orphanet Journal of Rare Diseases},
  number    = {1},
  doi       = {10.1186/s13023-022-02176-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300440},
  year      = {2022},
  abstract  = {Background In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. Study design This multi-center, prospective controlled study has a two-phase cohort design. Methods Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD's outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). Outcomes Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30\% in standard care to 40\% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients' quality of life and evaluation of care; and f) physicians' satisfaction with the innovative care approach. Conclusions This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease.},
  language  = {en}
}
@article{LorenzMusacchioKunstmannetal.2022,
  author    = {Lorenz, Delia and Musacchio, Thomas and Kunstmann, Erdmute and Grauer, Eva and Pluta, Natalie and Stock, Annika and Speer, Christian P. and Hebestreit, Helge},
  title     = {A case report of Sanfilippo syndrome - the long way to diagnosis},
  series = {BMC Neurology},
  volume    = {22},
  journal   = {BMC Neurology},
  number    = {1},
  doi       = {10.1186/s12883-022-02611-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300465},
  year      = {2022},
  abstract  = {Background Mucopolysaccharidosis type III (Sanfilippo syndrome) is a lysosomal storage disorder, caused by a deficiency in the heparan-N-sulfatase enzyme involved in the catabolism of the glycosaminoglycan heparan sulfate. It is characterized by early nonspecific neuropsychiatric symptoms, followed by progressive neurocognitive impairment in combination with only mild somatic features. In this patient group with a broad clinical spectrum a significant genotype-phenotype correlation with some mutations leading to a slower progressive, attenuated course has been demonstrated. Case presentation Our patient had complications in the neonatal period and was diagnosed with Mucopolysaccharidosis IIIa only at the age of 28 years. He was compound heterozygous for the variants p.R245H and p.S298P, the latter having been shown to lead to a significantly milder phenotype. Conclusions The diagnostic delay is even more prolonged in this patient population with comorbidities and a slowly progressive course of the disease.},
  language  = {en}
}
@article{MartinRommelThomasetal.2022,
  author    = {Martin, Tamara and Rommel, Kathrin and Thomas, Carina and Eymann, Jutta and Kretschmer, Tanita and Berner, Reinhard and Lee-Kirsch, Min Ae and Hebestreit, Helge},
  title     = {Seltene Erkrankungen in den Daten sichtbar machen - Kodierung},
  series = {Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz},
  volume    = {65},
  journal   = {Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz},
  number    = {11},
  doi       = {10.1007/s00103-022-03598-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-324275},
  pages     = {1133-1142},
  year      = {2022},
  abstract  = {Seltene Erkrankungen (SE) werden durch die im deutschen Gesundheitssystem verwendete Diagnosenklassifikation ICD-10-GM (International Statistical Classification of Diseases and Related Health problems, 10th Revision, German Modification) nur zu einem kleinen Teil eindeutig erfasst. Daher sind Aussagen zur H{\"a}ufigkeit von SE sowie zum speziellen Versorgungs- und Finanzierungsbedarf nicht m{\"o}glich, was zu einer l{\"u}ckenhaften Datenlage als Entscheidungsgrundlage f{\"u}r Krankenkassen, Leistungserbringer und Gesundheitspolitik f{\"u}hrt. Das Fehlen exakter Informationen behindert auch die wissenschaftliche Arbeit. Daher wird deutschlandweit ab 2023 die Verwendung der Alpha-ID-SE-Datei und der ORPHAcodes f{\"u}r die spezifische Erfassung von SE bei station{\"a}ren F{\"a}llen verpflichtend. Die Alpha-ID-SE-Datei verkn{\"u}pft die ICD-10-GM-Kodes mit den international anerkannten ORPHAcodes f{\"u}r die Diagnose von SE. Kommerzielle Anbieter stellen zunehmend die ben{\"o}tigten IT-Tools zur Kodierung von SE zur Verf{\"u}gung. An mehreren Universit{\"a}tskliniken mit Zentren f{\"u}r SE wurden L{\"o}sungen etabliert, die eine vollst{\"a}ndige Kodierung gew{\"a}hrleisten sollen. Hierzu geh{\"o}ren finanzielle Anreize f{\"u}r die kodierenden Bereiche, konkrete Nachfragen nach dem Vorliegen einer SE beim Kodiervorgang und eine semiautomatische Kodierung bei Patient*innen, die schon einmal mit einer SE an der Einrichtung betreut worden waren. Eine Kombination der verschiedenen Ans{\"a}tze verspricht die h{\"o}chste Wahrscheinlichkeit einer vollst{\"a}ndigen Kodierung. F{\"u}r ein umf{\"a}ngliches Bild der SE im Gesundheitssystem und um dem speziellen Versorgungs- und Finanzierungsbedarf besser Rechnung tragen zu k{\"o}nnen, w{\"a}re auch im ambulanten Bereich eine m{\"o}glichst spezifische und eindeutige Kodierung w{\"u}nschenswert. F{\"u}r komplexe SE und bisher undiagnostizierte Patient*innen wird zus{\"a}tzlich eine strukturierte Erfassung des Ph{\"a}notyps ben{\"o}tigt.},
  language  = {de}
}